INVIVO THERAPEUTICS HOLDINGS CORP.: Nasdaq/NYSE listing notice — InVivo Therapeutics receives Nasdaq delisting notice after Chapter 11 filing; trading to suspend Feb 13

INVIVO THERAPEUTICS HOLDINGS CORP.

Filed Chapter 11 bankruptcy on Feb 1, 2024.
Nasdaq notified company of delisting on Feb 2, 2024, per Listing Rules 5101, 5110(b), IM-5101-1.
Company will not appeal; common stock to be suspended at opening of business on Feb 13, 2024.
Form 25-NSE will be filed removing securities from Nasdaq listing and registration.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

INVIVO THERAPEUTICS HOLDINGS CORP. received a nasdaq delisting notice notice regarding other (rules 5101, 5110(b), IM-5101-1).

Exchange: nasdaq
Notice: delisting notice
Rules: 5101, 5110(b), IM-5101-1

Exact text from the filing

February 2, 2024, the Company received a notice from the Listing Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, as a result of the Voluntary Petitions and in accordance with Nasdaq Listing Rules 5101, 5110(b) and IM-5101-1, Nasdaq had determined that the Company’s common stock will be delisted from Nasdaq. The Company does not intend to appeal this determination and, therefore, it is expected that its common stock will be delisted, which would not affect any actions it may take in bankruptcy. Nasdaq has informed the Company that trading of the C

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001104659-24-010941

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.